UK markets close in 7 hours 49 minutes
  • FTSE 100

    6,989.21
    +80.45 (+1.16%)
     
  • FTSE 250

    17,537.93
    +253.05 (+1.46%)
     
  • AIM

    814.15
    +5.42 (+0.67%)
     
  • GBP/EUR

    1.1552
    +0.0036 (+0.32%)
     
  • GBP/USD

    1.1411
    +0.0091 (+0.81%)
     
  • BTC-GBP

    17,446.11
    +540.28 (+3.20%)
     
  • CMC Crypto 200

    452.63
    +17.28 (+3.97%)
     
  • S&P 500

    3,678.43
    +92.81 (+2.59%)
     
  • DOW

    29,490.89
    +765.38 (+2.66%)
     
  • CRUDE OIL

    83.90
    +0.27 (+0.32%)
     
  • GOLD FUTURES

    1,717.00
    +15.00 (+0.88%)
     
  • NIKKEI 225

    26,992.21
    +776.42 (+2.96%)
     
  • HANG SENG

    17,079.51
    -143.32 (-0.83%)
     
  • DAX

    12,414.77
    +205.29 (+1.68%)
     
  • CAC 40

    5,911.60
    +117.45 (+2.03%)
     

Relief Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

·3-min read

Relief Therapeutics Holding SA / Key word(s): Conference
Relief Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
07.09.2022 / 07:00 CET/CEST

Relief Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

Geneva, Switzerland, September 7, 2022 – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (“Relief”), a Swiss, commercial-stage biopharmaceutical company seeking to provide patients therapeutic benefit from selected specialty, rare and ultra-rare diseases with high unmet need, today announced that Jack Weinstein, Chief Financial Officer and Treasurer, will present a company overview during the H.C. Wainwright 23rd Annual Global Investment Conference, being held September 12-14, 2022.

Date: Tuesday, September 13, 2022
Time: 1:30 pm ET

Management will host one-on-one meetings during the event. Institutional investors who are registered for the conference can log into www.hcwevents.com to request a meeting with the company.

A live webcast of Relief’s presentation will be available on the Company’s website at: https://www.relieftherapeutics.com/news-and-events and will be archived for a period of 90 days after the conference.


ABOUT RELIEF

Relief is a Swiss, commercial-stage, biopharmaceutical company focused on identification, development and commercialization of novel, patent protected products intended for the treatment of rare and ultra-rare diseases including metabolic disorders, pulmonary diseases and connective tissue disorders. Relief’s diversified pipeline consists of assets that have the potential to effectively address significant unmet medical needs, including PKU GOLIKE®, engineered with the proprietary Physiomimic technology, which is the first prolonged-release amino acid product commercialized for the dietary management of phenylketonuria ("PKU"). Relief has a Collaboration and License Agreement with Acer Therapeutics for the worldwide development and commercialization of ACER-001 (sodium phenylbutyrate) for the treatment of various inborn errors of metabolism, including Urea Cycle Disorders (“UCDs”) and Maple Syrup Urine Disease (MSUD). Relief also continues to develop aviptadil for several rare pulmonary indications. Relief is in clinical development for APR-TD011, a differentiated acid oxidizing solution of hypochlorous acid intended for the treatment of epidermolysis bullosa ("EB"), a group of rare, genetic, life-threatening connective tissue disorders; APR-TD011 has been granted Orphan Drug Designation by the FDA. In addition, Relief is commercializing several legacy products via licensing and distribution partners.

RELIEF THERAPEUTICS Holding AG is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTY. For more information, visit www.relieftherapeutics.com. Follow Relief on LinkedIn.

CONTACT:
RELIEF THERAPEUTICS Holding AG
Jack Weinstein
Chief Financial Officer and Treasurer
contact@relieftherapeutics.com

FOR MEDIA/INVESTOR INQUIRIES:
Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com

 

 

Additional features:

File: Press release

End of Media Release

Language:

English

Company:

Relief Therapeutics Holding SA

Avenue de Secheron 15

1202 Geneva

Switzerland

Phone:

+41 22 545 11 16

E-mail:

contact@relieftherapeutics.com

Internet:

https://relieftherapeutics.com

ISIN:

CH0100191136

Valor:

10019113

Listed:

SIX Swiss Exchange

EQS News ID:

1436833


 

End of News

EQS News Service

show this
show this